Anti-IgE was associated with a lower risk of congestive heart failure, peripheral artery disease, and stroke, whereas anti-IL5/IL5R therapy was associated with a lower risk of congestive heart failure, arrythmia, and peripheral artery disease compared with similar eligible non-biologic users. The gene discussed is IL5; the disease is peripheral arterial disease.